葛兰心宁软胶囊治疗冠心病临床疗效及对血清ICAM-1和AngⅡ影响

Clinical Efficacy of Gelan Xinning Soft Capsule in Treatment of Coronary Heart Disease and Its Effect on Serum ICAM-1 and Ang Ⅱ

目的观察葛兰心宁软胶囊治疗冠心病不稳定型心绞痛(痰瘀互结型)患者的临床疗效及对血清ICAM-1和AngⅡ的影响。方法本研究选取符合纳入标准并自愿参与该研究的痰瘀互结型不稳定型心绞痛患者160例,将其随机分为对照组与治疗组,每组各80例。对照组予西医常规治疗,治疗组在对照组的基础上加以葛兰心宁软胶囊,35 d为1个疗程。观察两组患者治疗前后的临床疗效及血清ICAM-1和AngⅡ的变化。结果在心绞痛症状积分及中医证候积分方面,两组患者在治疗后较治疗前均显著降低(P<0.01);治疗后,治疗组患者积分的降低程度较对照组更为明显(P<0.01)。在心绞痛症状疗效及中医证候疗效方面,两组患者治疗后较治疗前均显著降低(P<0.01);治疗后,治疗组患者积分的降低成度较对照组更为明显(P<0.01)。治疗后,两组患者血清ICAM-1含量较治疗前显著降低(P<0.01),血清AngⅡ含量较治疗前显著降低(P<0.01)。治疗后,治疗组血清ICAM-1含量显著低于对照组(P<0.01),治疗组血清AngⅡ含量显著低于对照组(P<0.01)。结论葛兰心宁软胶囊可改善冠心病不稳定型心绞痛痰瘀互结型患者的临床疗效,其作用机制可能与血清ICAM-1和AngⅡ含量的降低有关,从而降低炎症反应,起到抗动脉粥样硬化的作用。

Objective:To observe the clinical efficacy of Gelan Xinning Soft Capsule in the treatment of unstable angina pectoris(phlegm-blood stasis syndrome)and its effect on serum ICAM-1 and Ang Ⅱ.Methods:160 patients with unstable angina pectoris of phlegm-blood stasis type who met the inclusion criteria and volunteered to participate in the study were randomly divided into control group and treatment group,80 cases in each group.The control group was given routine western medicine treatment,while the treatment group was given Gelan Xinning Soft Capsule on the basis of the control group,35 days as a course of treatment.The clinical efficacy and changes of serum ICAM-1 and Ang Ⅱ were observed before and after treatment.Results:The scores of angina symptoms and TCM syndromes in both groups were significantly lower after treatment than before treatment(P<0.01);after treatment,the scores of patients in the treatment group were significantly lower than those in the control group(P<0.01).In terms of the curative effect of angina pectoris symptoms and TCM syndromes,the two groups of patients after treatment were significantly lower than before treatment(P<0.01);after treatment,the scores of patients in the treatment group were significantly lower than those in the control group(P<0.01).After treatment,the serum ICAM-1 and Ang Ⅱ levels in the two groups were significantly lower than those before treatment(P<0.01),respectively(P<0.01).After treatment,the serum ICAM-1 level in the treatment group was significantly lower than that in the control group(P<0.01),and the serum AngⅡ level in the treatment group was significantly lower than that in the control group(P<0.01).Conclusion:Gelan Xinning Soft Capsule can improve the clinical efficacy of unstable angina pectoris patients with phlegm-blood stasis syndrome.Its mechanism may be related to the decrease of serum ICAM-1 and Ang II levels,which can reduce inflammation and play an anti-atherosclerosis role.